Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo …
AL Cheng, YK Kang, Z Chen, CJ Tsao, S Qin… - The lancet …, 2009 - thelancet.com
Background Most cases of hepatocellular carcinoma occur in the Asia-Pacific region, where
chronic hepatitis B infection is an important aetiological factor. Assessing the efficacy and …
chronic hepatitis B infection is an important aetiological factor. Assessing the efficacy and …
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 …
Z Ren, J Xu, Y Bai, A Xu, S Cang, C Du, Q Li… - The Lancet …, 2021 - thelancet.com
Background China has a high burden of hepatocellular carcinoma, and hepatitis B virus
(HBV) infection is the main causative factor. Patients with hepatocellular carcinoma have a …
(HBV) infection is the main causative factor. Patients with hepatocellular carcinoma have a …
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled …
L Paz-Ares, M Dvorkin, Y Chen, N Reinmuth, K Hotta… - The Lancet, 2019 - thelancet.com
Background Most patients with small-cell lung cancer (SCLC) have extensive-stage disease
at presentation, and prognosis remains poor. Recently, immunotherapy has demonstrated …
at presentation, and prognosis remains poor. Recently, immunotherapy has demonstrated …
Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous …
H Luo, J Lu, Y Bai, T Mao, J Wang, Q Fan, Y Zhang… - Jama, 2021 - jamanetwork.com
Importance Standard first-line therapy for advanced or metastatic esophageal carcinoma is
chemotherapy, but the prognosis remains poor. Camrelizumab (an anti–programmed death …
chemotherapy, but the prognosis remains poor. Camrelizumab (an anti–programmed death …
[PDF][PDF] Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial
ZX Wang, C Cui, J Yao, Y Zhang, M Li, J Feng, S Yang… - Cancer cell, 2022 - cell.com
Platinum-based chemotherapy is the standard first-line treatment for advanced esophageal
squamous cell carcinoma (ESCC). In this phase 3 study (ClinicalTrial. gov: NCT03829969) …
squamous cell carcinoma (ESCC). In this phase 3 study (ClinicalTrial. gov: NCT03829969) …
Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a …
J Huang, J Xu, Y Chen, W Zhuang, Y Zhang… - The Lancet …, 2020 - thelancet.com
Background Patients with advanced or metastatic oesophageal squamous cell carcinoma
have poor prognosis and few treatment options after first-line therapy. We aimed to assess …
have poor prognosis and few treatment options after first-line therapy. We aimed to assess …
[HTML][HTML] Donafenib versus sorafenib in first-line treatment of unresectable or metastatic hepatocellular carcinoma: a randomized, open-label, parallel-controlled phase …
S Qin, F Bi, S Gu, Y Bai, Z Chen, Z Wang… - Journal of Clinical …, 2021 - ncbi.nlm.nih.gov
PURPOSE Donafenib, a novel multikinase inhibitor and a deuterated sorafenib derivative,
has shown efficacy in phase Ia and Ib hepatocellular carcinoma (HCC) studies. This study …
has shown efficacy in phase Ia and Ib hepatocellular carcinoma (HCC) studies. This study …
Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial
S Qin, Z Ren, Z Meng, Z Chen, X Chai, J Xiong… - The Lancet …, 2020 - thelancet.com
Background Blocking the interaction between PD-1 and its ligands is a promising treatment
strategy for advanced hepatocellular carcinoma. This study aimed to assess the antitumour …
strategy for advanced hepatocellular carcinoma. This study aimed to assess the antitumour …
Effect of first-line serplulimab vs placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer: the ASTRUM-005 randomized …
Y Cheng, L Han, L Wu, J Chen, H Sun, G Wen, Y Ji… - Jama, 2022 - jamanetwork.com
Importance Programmed cell death ligand 1 inhibitors combined with chemotherapy has
changed the approach to first-line treatment in patients with extensive-stage small cell lung …
changed the approach to first-line treatment in patients with extensive-stage small cell lung …
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international …
S Qin, SL Chan, S Gu, Y Bai, Z Ren, X Lin, Z Chen… - The Lancet, 2023 - thelancet.com
Background Immunotherapy with immune checkpoint inhibitors combined with an anti-
angiogenic tyrosine-kinase inhibitor (TKI) has been shown to improve overall survival versus …
angiogenic tyrosine-kinase inhibitor (TKI) has been shown to improve overall survival versus …